Trial Profile
A randomized, double-blind, placebo-controlled, dose-ranging, multi-center study to evaluate the cardiovascular and cerebrvascular effects of MC-1 in patients undergoing high-risk coronary artery bypass graft (CABG) surgery.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Pyridoxal phosphate (Primary)
- Indications Coronary artery disease; Coronary disorders; Myocardial infarction; Stroke
- Focus Therapeutic Use
- Acronyms MEND-CABG
- 03 Nov 2006 Status change
- 11 Nov 2005 New trial record.